



## **Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses And Opportunistic Infections 2022**

February 8, 2022

CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e. COVID-19), today announced that a late-breaker poster presentation sharing clinical data from the ongoing PBI-0451 Phase 1 trial will be presented at the 29th Conference On Retroviruses And Opportunistic Infections (CROI) 2022, to be held virtually from February 12-16, 2022.

### **Details of Pardes' poster presentation:**

**Title:** PBI-0451 an orally administered 3CL protease inhibitor of SARS-CoV-2 for COVID-19

**Abstract Number:** 00470

**Session:** New Antivirals for SARS-CoV-2: Activity *in vitro* and *in vivo*

**Poster Number:** H02

**Presentation Date and Time:** Tuesday, February 15, 2022, 1:00 – 2:30 p.m. PT

The full poster will be placed on Pardes' website following the presentation.

### **About Pardes Biosciences, Inc.**

Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company's lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections and associated diseases (i.e. COVID-19), the virus responsible for COVID-19. For more information, please visit [www.pardesbio.com](http://www.pardesbio.com).

### **About PBI-0451**

PBI-0451 is an investigational orally bioavailable direct-acting antiviral (DAA) inhibitor of the main protease (Mpro), an essential protein required for the replication of coronaviruses, including the novel SARS-CoV-2 that causes COVID-19. This protease is highly similar across all coronaviruses, including known and emerging coronavirus variants. PBI-0451 is being developed for the treatment and prevention of SARS-CoV-2 infection and associated diseases. PBI-0451 is currently in a Phase 1 placebo-controlled, blinded, randomized, dose escalation study in healthy volunteers in New Zealand evaluating the safety, tolerability, and pharmacokinetics of PBI-0451 after single and multiple ascending doses. For more information, please visit [www.pardesbio.com](http://www.pardesbio.com).

### **Availability of Other Information about Pardes Biosciences**

Pardes intends to use the Investors page of its website (<https://ir.pardesbio.com>) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD (Fair Disclosure). Accordingly, investors should monitor Pardes' Investors website, in addition to following Pardes' press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

### **Investor Contact:**

[ir@pardesbio.com](mailto:ir@pardesbio.com)

Stephen Jasper  
Gilmartin Group  
(858) 525-2047  
[stephen@gilmartinir.com](mailto:stephen@gilmartinir.com)